Takeda Takes Back Actos Rights from Eli Lilly, Sets Course For Own Geographic Expansion
This article was originally published in PharmAsia News
Executive Summary
Takeda is taking back marketing rights to type 2 diabetes treatment Actos (pioglitazone) from Eli Lilly in Canada and six other countries as early as this year, according to the two companies
You may also be interested in...
From Product Launches To Toll Manufacturing, Japanese Giant Takeda Unveils Plans For India
MUMBAI - Almost a year after naming former Roche executive Shankar Suryanarayanan as head of its Indian operations, Japan's largest drug maker Takeda has unveiled "medium- to long-term strategies" for its business expansion - one of which is to launch its products in the burgeoning Indian market
From Product Launches To Toll Manufacturing, Japanese Giant Takeda Unveils Plans For India
MUMBAI - Almost a year after naming former Roche executive Shankar Suryanarayanan as head of its Indian operations, Japan's largest drug maker Takeda has unveiled "medium- to long-term strategies" for its business expansion - one of which is to launch its products in the burgeoning Indian market
Takeda Takes Global Expansion Next Door To South Korea
TOKYO - Takeda, Japan's largest drug manufacturer by sales, made an announcement June 23 that may come as a surprise. This year, the company hopes to establish its own commercial presence in South Korea, one of Japan's closest neighbors and one of Asia's largest markets